Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
In the recent KEYNOTE-564 trial, adjuvant pembrolizumab therapy was shown to increase the 48-month overall survival rate to 91.2% compared to 86.0% with placebo among post-surgical patients with renal-cell carcinoma at increased risk of recurrence.
Oncology, Medical April 29th 2024
Cancer Therapy Advisor
Explore the latest insights from ASCO GU 2024 on first-line treatments for advanced renal cell carcinoma, including the effectiveness of combination therapies and the pressing need to address racial disparities in patient outcomes.
Oncology, Medical April 1st 2024
In the KEYNOTE-564 trial, adjuvant pembrolizumab demonstrated a significant improvement in disease-free survival among patients with renal-cell carcinoma at high risk of recurrence after nephrectomy, offering a new direction in post-surgical treatment strategies.
Nephrology February 20th 2024
Dana-Farber Cancer Institute
In the landmark KEYNOTE-564 trial, pembrolizumab has emerged as a pivotal advancement in kidney cancer treatment, offering hope by significantly prolonging survival in patients with high-risk ccRCC post-nephrectomy.
Oncology, Medical February 12th 2024
OBR Oncology
Pembrolizumab now represents a transformative advancement in the adjuvant treatment of clear cell renal cell carcinoma, significantly reducing the risk of progression or death by 38% compared to placebo.
Oncology, Medical February 5th 2024
Belzutifan’s FDA approval, following the LITESPARK-005 trial results, represents a significant stride in treating advanced kidney cancer, offering a novel therapeutic option for patients who have exhausted standard treatments.
Nephrology January 8th 2024